GlassScriptPhysician profile
Richard A Nance
NPI 1447232863
$438.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $117 · 2021: $145.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $121.98 | 2019-2020 | |
| Novo Nordisk INC | $55.77 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $40.19 | 2020-2021 | |
| Abbvie INC. | $33.83 | 2021 | |
| Hikma Pharmaceuticals USA | $33.05 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.27 | 2021 | |
| Pfizer INC. | $19.07 | 2020 | |
| Amgen INC. | $18.37 | 2021 | |
| Astellas Pharma US INC | $18.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.87 | 2020 | |
| Indivior INC. | $15.62 | 2021 | |
| Amarin Pharma, INC. | $14.99 | 2020 | |
| Abbott Laboratories | $13.81 | 2021 | |
| Lilly USA, LLC | $11.94 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.